Mirtazapine 15 Viatris, Mirtazapine 30 Viatris 15 mg & 30mg FC tablets.
PDF Leaflet Revision Date: 22 October 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of major depressive illness in adults.
Dosage (summary)
Initial dose: 15 mg, usual range: 15-45 mg.
Onset of Action / Duration
Onset: 1-2 weeks, Duration: 6 months for acute episodes.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation due to insufficient data.
Key Drug Interactions
- MAO inhibitors
- Alcohol
- Serotonergic agents
Contraindications
- Hypersensitivity to mirtazapine
- Children under 18 years
- Concomitant MAO inhibitors
Common side effects
- Somnolence
- Sedation
- Dry mouth
- Weight increase
- Dizziness
Counselling Points
- Take preferably at night
- Avoid alcohol
- Monitor for suicidal thoughts
Serious warnings
- Suicidal thoughts
- Severe cutaneous adverse reactions
- Bone marrow depression
Important Disclaimer
The Mirtazapine 15 Viatris, Mirtazapine 30 Viatris 15 mg & 30mg FC tablets. professional information leaflet below is the property of Viatris South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
